Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.

Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.

Abstract: A stable dispersion of insoluble collagen is provided by a microfluidization process. The dispersions of insoluble collagen protein remain in stable suspension under long term storage conditions, with minimal or no settling or precipitation. More specifically the invention provides a stable dispersion of insoluble collagen comprising collagen particles wherein 50% by volume of said particles are less than 30 micrometers in width. These dispersions provide collagen in an aqueous form, which enables ease of incorporation into food and beverages and ease of administration to people or other mammals in need of collagen.

Abstract: One aspect of the present invention relates to a method of preparing a fibrous protein smectic hydrogel by way of a solvent templating process, comprising the steps of pouring an aqueous fibrous protein solution into a container comprising a solvent that is not miscible with water; sealing the container and allowing it to age at about room temperature; and collecting the resulting fibrous protein smectic hydrogel and allowing it to dry.

Abstract: The present invention relates to the enhancement of the efficacy of drugs, and more particularly, with overcoming the resistance of cells or organisms to drugs. In particular, the present invention provides a method for enhancing the effectiveness of a cytotoxic or anti-neoplastic agent, comprising the step of co-administering said agent with hyaluronan, wherein co-administration with hyaluronan enhances the agent's cancer cell-killing potential.

Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.

Abstract: The invention comprises a method of making molded, double-crosslinked (i.e., two stages of crosslinking), transparent, collagen materials using a novel combination of diafiltration, lyophilization, and homogenization. The collagen material can be used not only as an ophthalmic device, but also as a tissue scaffold, drug delivery device, wound dressing, or other collagen hydrogel based device.

Abstract: This invention provides for compositions, methods and devices for rapidly converting silk fibroin solution into a silk fibroin gel using direct application of voltage, in a process called electrogelation. The silk fibroin gel may be reversibly converted back to liquid form by applying reverse voltage or may be converted further to ?-sheet structure by applying shear force or other treatments. The electrogelated silk may be used as an extracted bulk gel, spray or stream of gel for processing into materials or devices, or may be used as silk gel coating to devices. Active agents may be embedded in the silk gel for various medical applications. This invention also provides for methods and compositions for preparing adhesive silk pH-gels. For example, the method comprises reducing pH level of a silk fibroin solution to increase the bulk or local proton concentration of the silk fibroin solution, thereby forming adhesive silk gels.

Abstract: Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.

Abstract: A hydrogel that includes an aqueous solution or an alcohol aqueous solution, and a hydrogelator containing a lipid peptide represented by Formula (1), or a pharmaceutically usable salt thereof. In Formula (1), R1 represents an aliphatic group having 9 to 21 carbon atoms; R2, R3, and R4 independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms that optionally has a branched chain having 1 or 2 carbon atoms, a phenylmethyl group, or a —(CH2)n—X group, and at least one of R2, R3, and R4 represents a —(CH2)n—X group; n represents an integer from 1 to 4; and X represents an amino group, a guanidino group, a —CONH2 group, or a 5-membered ring, a 6-membered ring or a fused heterocyclic ring composed of a 5-membered ring and a 6-membered ring that optionally has 1 to 3 nitrogen atoms.

Abstract: Disclosed herein are personal care compositions having at least one oligopeptide self-assembled into nanofibers or macrostructures, wherein the oligopeptide is 2-20 amino acids in length, and wherein the oligopeptide has at least one 0- to 10-amino-acid block of hydrophobic amino acids alternating with at least one 1- to 10-amino-acid block of hydrophilic amino acid residues. The composition may further include a dermatologically acceptable carrier and at least one cosmetic skin care agent.

Abstract: Compositions that contain bioactive agent-loaded nanoparticles with heart targeting capabilities and methods of using the same for the treatment of disease are disclosed.

Abstract: A production method of a cosmetic that includes blending at least one lipid peptide-type gelator that contains a low-molecular lipid peptide or a pharmaceutically usable salt thereof at a ratio of 0.1% by weight to 0.5% by weight based on a mass of the polymer thickener to form a thickening gel; a preparation method of a gel for cosmetics that includes blending, into an aqueous medium for cosmetics, a polymer thickener and at least one lipid peptide-type gelator that contains a low-molecular lipid peptide or a pharmaceutically usable salt thereof at the above-mentioned ratio to form a gel; and a method of reducing the use amount of a polymer thickener in production of a cosmetic that includes blending at least one lipid peptide-type gelator that contains a low-molecular lipid peptide or a pharmaceutically usable salt thereof at the above-mentioned ratio.

Abstract: Provided is an adhesion preventing medical material including a bioresorbable base material and a polyhydric alcohol or aqueous polyhydric alcohol solution, which contains the polyhydric alcohol, held in the bioresorbable base material. The bioresorbable base material includes a bioresorbable material, and has a swelling degree of 200 to 3,000 mass % and a water elution rate of not higher than 10 mass %. After immersed for 3 hours in water of 25° C. in an amount at least 50 times a total mass of the aqueous polyhydric alcohol solution or aqueous polyhydric alcohol solution and the bioresorbable base material, the polyhydric alcohol remains in an amount of not greater than 30 mass % of that of the polyhydric alcohol before the immersion.

Abstract: The invention relates to a method for producing a multi-layer collagen scaffold. The method generally comprises the steps of: preparing a first suspension of collagen and freezing or lyophilising the suspension to provide a first layer; optionally preparing a further suspension of collagen and adding the further suspension onto the layer formed in the previous step to form a further layer, and freezing or lyophilising the layers, wherein when the layer formed in the previous step is formed by lyophilisation the lyophilised layer is re-hydrated prior to addition of the next layer; optionally, repeating the aforementioned step to form one or more further layers; and preparing a final suspension of collagen and pouring the final suspension onto the uppermost layer to form a final layer, and freeze-drying the layers to form the multi-layer collagen composite scaffold.

Abstract: The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.

Abstract: A vehicle composition in the form of a vesicular composition or a particular composition and, optionally, an active agent associated with the vesicle forming components or particles, and folate receptor alpha is used as a delivery system for the transport of components and/or active agents into the cerebrospinal fluid (CSF) and/or brain and/or central nervous system and/or spinal cord. The composition is used for treating of CSF or brain pertaining diseases, disorders or conditions, such as preventing or treating neurological or neurodegenerative diseases, disorders or conditions.

Abstract: The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer.

Abstract: The present invention is directed to topical compositions, comprising isoflavone nanoparticle compositions. The isoflavone nanoparticle compositions contain isoflavone in the form of nanoparticles and preferably a carrier. In the topical compositions recrystallization of the isoflavone to bigger particles is avoided.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.

Abstract: A polypeptide based block copolymer having biodegradability due to peptidase, a process for the preparation thereof, and polymer micelles using the same are provided. The block copolymer is a block copolymer of a polyethylene glycol-based compound having properties such that the solubility for water is different depending on the pH, but cannot form micelles due to a self-assembly phenomenon; and a polyglutamic acid-based compound formed using an aminolysis reaction of glutamic acid and tertiary amine in which the end of one alkyl group is substituted with NH2, or using an aminolysis reaction of glutamic acid and triamine.

Abstract: This disclosure describes, in one aspect, a method that generally includes combining a silica precursor and a biocompatible polymer under conditions effective for the silica precursor and the biocompatible polymer to form a gel, at least partially dehydrating the gel, and rehydrating the gel. This disclosure also describes a corneal implant prepared by any embodiment of the general method described herein.

Abstract: (Modified) rice endosperm protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) rice endosperm protein and at least one active ingredient and to their manufacture, as well as to the (modified) rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) rice endosperm protein and such a composition, respectively.

Abstract: Embodiments of the present invention encompass compositions containing an adipose derived carrier, matrix, or filler, in some cases optionally in combination with bone particles or other granular materials or substances, for delivery to a human patient. Methods of manufacture and use of such adipose derived compositions are also disclosed.

Abstract: An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device also has particles carried on the base body, wherein the particles are composed of a different material from that of the base body. The organ regeneration device also has a growth-related substance contained in the organ regeneration device for growth and differentiation of cells around the defective portion. The growth-related substance contains an angiogenesis factor. Further, the growth-related substance contains nucleic acid containing a base sequence coding for amino-acid sequence of a growth factor different from the angiogenesis factor. Furthermore, the nucleic acid is introduced into a host cell.

Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.

Abstract: The invention relates to continuous fiber layers comprising an active substance on the basis of bio-polymers, comprising a fibrous, bio-polymer active substance carrier, and at least one active substance associated with the carrier and releasable from the continuous fiber layer; to formulations comprising an active substance, the formulations comprising such continuous fiber layers; to the use of continuous fiber layers comprising an active substance for the production of formulations comprising an active substance; and to a method for the production of continuous fiber layers comprising an active substance. The invention further relates to corresponding continuous fiber layers comprising an active substance and to the use thereof for the production of wound treatment and hygiene products, and to the respectively produced wound treatment and hygiene products.

Abstract: A synthetic vitreous material contains a self-assembling peptide and a salt, and has an osmotic pressure of 40 mOsm/kg to 200 mOsm/kg. Such a synthetic vitreous material is not toxic to ocular tissue, is capable of maintaining an intraocular tamponade effect over a long term, and is easy to handle and inject into an eye of a patient.

Abstract: The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.

Abstract: A thiol-yne polymeric material and methods for producing said polymers are disclosed. The material is produced by the radically mediated polymerization of monomers having alkyne and thiol functional groups. The alkyne moiety, internal or terminal, may react with one or two thiols. Degradable monomers may be used to form degradable polymers.

Abstract: In a first aspect, the invention provides a polymeric nanoparticle comprising at least one polycationic polymer; at least one polyanionic polymer; and a therapeutically effective amount of at least one therapeutic agent. In a second aspect, the invention provides a method for the preparation of a polymeric nanoparticle according to the first aspect; the method comprising the steps of: (i) admixing the at least one polyanionic polymer with the at least one therapeutic agent; and (ii) introducing to the mixture of (i), to the at least one polycationic polymer. In a third aspect, the invention provides a polymeric nanoparticle according to the first aspect of the present invention, or a polymeric nanoparticle prepared according to the second aspect of the present invention; for use in the treatment of an inflammatory and/or arthritic disorder caused by or associated with dysfunctional nuclear receptor signalling.

Abstract: The present invention relates to artificial oil bodies comprising oleosin (which, as presently defined, also encompasses caleosin, steroleosin and polyoleosin), a surfactant such as a phospholipid, and an oil comprising fatty acids, such as polyunsaturated fatty acids having four or more double bonds. The present invention also relates to methods of preparing said artificial oil bodies. These AOBs may further comprise other molecules such as bioactive molecules, used in a wide variety of products, and are particularly useful for producing oxidatively stable oil-in-water emulsions in the absence of added antioxidants. The present invention further encompasses a method for the partial purification of oleosin from a plant extract.

Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.

Abstract: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Abstract: The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., insulin, glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.

Abstract: A biodegradable film (4) characterized in that it is prepared from at least one co-product derived from a soya bean-processing process aimed at obtaining soya-based final products by ultrafiltration, said co-product being selected from the group comprising the okara and the permeate. Such a film can be used as a food or pharmaceutical film, in particular for preparing a product for topical administration (1) of a pharmaceutical active ingredient, such as oestrogens.

Abstract: The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. The gel further contains proteins from the extracellular matrix that promote cell growth and density in and around the gel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect.

Abstract: Methods for delivering therapeutic agent(s) to the central nervous system to treat a first CNS-related disease and/or condition while avoiding systemic exposure for patients having a second concurrent non-CNS-related disease and/or condition wherein the presence of the second disease and/or condition contraindicates systemic administration of the therapeutic agent(s) and/or pharmaceutical compound to treat the first disease or condition. The present invention provides these advantages by applying the therapeutic agent(s) and/or pharmaceutical composition(s) to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and administering the therapeutic agent(s) and/or pharmaceutical compound(s) directly to the CNS.

Abstract: A biologically derived polymer that facilitates the solubilization and protection of small molecules for use in drug delivery, in which the polymer is a protein polymer. A biologically derived polymer that facilitates the solubilization and protection of small molecules for use in drug delivery, incorporating fluorinated amino acids into the protein polymer for visualization and detection by 19F NMR, 19F MRS, and 19F MRI.

Abstract: A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired shape, and a step for drying the collagen gel fragments arranged in the desired shape. Moreover, in one embodiment of the method for producing a collagen material a step may include imparting an orientation to the collagen gel fragments.

Abstract: (Modified) sorghum protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) sorghum protein and at least one active ingredient and to their manufacture, as well as to the (modified) sorghum protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) sorghum protein and such a composition, respectively.

Abstract: Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.

Abstract: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.

Abstract: Environmentally friendly and aerated topical benefit compositions are described. The compositions are emulsified with hydrophobin and upon topical application deliver excellent sensory and absorption characteristics along with consumer desirable drying times.

Abstract: Provided are fibrous composites prepared by methods of the present invention, comprising oxides and biodegradable polymers, in which the fibers are made of aerogel-like oxide materials having nanometer-sized pores. The fibrous composition advantageously has, at least, the following characteristics: (i) a very high nanoporous surface area, which also permits nucleation of crystallites; (ii) mesoporous/macroporous interspacial networks between the fibers, providing high bioactivity and a high transport rate; (iii) macropores for natural bone-like tissue growth; (iv) good mechanical properties for handling and for implant support; and (v) biodegradability for implant dissolution and time-variable mechanical properties. Further provided are methods for using the bioactive biodegradable fibrous composites as osteogenic composite materials for tissue engineering, tissue re-growth, bone implants, and bone repair, and/or for the delivery of drugs or therapeutic compounds.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: Compositions for an oral delivery vehicle are described as well as methods for their manufacture and administration. The oral delivery vehicles can be made in any size or shape and can further comprise a medicament or other substance or object to be orally delivered. The vehicle can, for example, take the form of a pouch or capsule. Alternatively, a medicament or other substance to be orally delivered can be coated with the composition. In another alternative, the medicament or other substance to be orally delivered can be dispersed within a matrix of the composition. The compositions for the oral delivery vehicle are also suitable for use as an animal food or treat or use as a hunting bait or lure.

Abstract: The present invention is directed to a composite laminar material with high mechanical strength and methods of fabricating the material. The invention also provides a method of attaching a medical implant device to tissue.

Abstract: A plurality of amphiphilic peptide chains having alternating hydrophilic and hydrophobic amino acids, wherein the peptide contains at least 8 amino acids, are complementary and structurally compatible, and self-assemble into a beta-sheet macroscopic scaffold wherein peptide at least about 75% of the chains have the same sequence.